{
    "Trade/Device Name(s)": [
        "Alere BinaxNOW\u00ae Influenza A & B Card"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K133411",
    "Predicate Device Reference 510(k) Number(s)": [
        "K092223"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "December 5, 2013",
    "Summary Letter Received Date": "November 7, 2013",
    "Submission Date": "November 5, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.3330"
    ],
    "Regulation Name(s)": [
        "Influenza virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A nucleoprotein antigen",
        "Influenza B nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Nasal swab",
        "Nasal wash/aspirate"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic membrane assay",
        "Lateral flow immunoassay"
    ],
    "Methodologies": [
        "Immunochromatographic assay",
        "Antibody-based detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Card"
    ],
    "Document Summary": "FDA 510(k) summary for Alere BinaxNOW Influenza A & B Card rapid immunochromatographic assay for influenza A and B antigen detection in respiratory specimens",
    "Indications for Use Summary": "Qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal swab, nasal swab, and nasal wash/aspirate specimens to aid in the rapid differential diagnosis of influenza A and B viral infections; negative results are presumptive and should be confirmed by cell culture or FDA-cleared molecular assay",
    "fda_folder": "Microbiology"
}